Article
Merck's First-Quarter Earnings Beat Estimates. The Stock Is Rising.
Rating:
0.0
Views:
41
Likes:
1
Library:
1
The big pharma company has been getting ready for the loss of patent protection for the cancer immunotherapy Keytruda in 2028. Merck also raised guidance.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value